'Hike Doesn't Change Fundamentals,' says Cetera's Goldman
Source: Bloomberg
Cetera CIO Gene Goldman characterized the Fed's latest rate decision as a likely one- or two-hike insurance measure against sticky inflation rather than a return to aggressive tightening, arguing markets had priced in too much. Separately, a draft report found Fed officials did not adequately respond to repeated warnings about Silicon Valley Bank's deteriorating financial condition ahead of its 2023 collapse, renewing scrutiny of bank supervision.
Analysis
The actionable signal is a repricing from a sustained tightening regime toward a shallow policy-error premium. That should support duration-sensitive equities and reduce the near-term headwind to credit, but the upside is likely concentrated in high-quality balance sheets rather than lower-quality cyclicals: falling terminal-rate expectations ease discount rates immediately, while a still-restrictive real-rate backdrop limits broad earnings reacceleration over the next 1-3 months. The cleaner expression is long secular-duration quality versus short rate-sensitive financials with deposit or commercial-real-estate exposure.
The supervisory-review angle creates a separate, underappreciated regional-bank risk. Even without a new crisis, stricter examination standards can force smaller banks to hold more liquidity, pay up for deposits, and reduce securities-duration risk; all three compress NIM and constrain loan growth over 6-18 months. This is incrementally favorable for money-center banks (JPM, BAC) and cash-management platforms (SCHW, IBKR), which can absorb compliance costs and capture deposit migration, while pressuring KRE constituents with concentrated funding bases.
Consensus may overstate the equity upside from fewer hikes. A benign path requires inflation to soften without a renewed decline in labor-market resilience; otherwise, long-end yields can remain elevated even if policy rates stop rising, limiting multiple expansion in QQQ and unprofitable growth. Falsification of the regional-bank short bias would be a sustained decline in deposit betas, improving uninsured-deposit disclosure, and upward 2026 NII guidance; falsification of the duration-long thesis would be a meaningful reacceleration in core inflation or a sharp rise in term premium.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Key Decisions for Investors
- Initiate a 1-3 month pair: long QQQ / short KRE, sized beta-neutral. The trade captures easing terminal-rate expectations while isolating lingering funding, regulatory, and CRE risks in regional banks; reassess if the 10-year Treasury yield rises more than 40bp from entry or KRE banks broadly raise NII guidance.
- Prefer JPM over KRE for a 6-12 month structural expression of deposit consolidation and higher supervisory fixed costs. Use a 2:1 notional long JPM/short KRE spread; target 10-15% relative return, with risk defined by broad deposit-cost normalization and a steepening curve that restores regional-bank NIM.
- Add selectively to long-duration quality only after rate-volatility confirmation: buy QQQ or IWF on a sustained decline in MOVE rather than immediately chasing a post-decision rally. A 5-8% upside over 1-3 months is plausible from multiple stabilization, but exit if inflation data force renewed upward revisions to the policy-rate path.
- Avoid a broad long in bank ETFs until forthcoming bank disclosures show whether liquidity buffers and deposit pricing are improving. This is a watch item rather than a recommendation: the missing data are deposit beta trends, uninsured-deposit concentrations, HTM duration exposure, and CRE criticized-loan migration.
More News
- Three words from Kevin Warsh have Wall Street wondering how far the Fed will go with rate hikes
- Tokenization is set to change stock trading. These stocks could get a boost
- FTSE 100 today: Stocks drop as Hormuz tanker hit, Aramco cuts Europe supply
- Buffett Steps Down at Berkshire
- Exclusive-US weighs allowing most pharma licensing deals with China, sources say
- The Dow Is Down for a Third Straight Week and the Nasdaq Is Somehow Up